Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김태헌 | * |
dc.contributor.author | 김휘영 | * |
dc.contributor.author | 이민종 | * |
dc.contributor.author | 전호수 | * |
dc.contributor.author | 이한아 | * |
dc.date.accessioned | 2024-05-20T16:31:10Z | - |
dc.date.available | 2024-05-20T16:31:10Z | - |
dc.date.issued | 2024 | * |
dc.identifier.issn | 1743-9159 | * |
dc.identifier.other | OAK-34895 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/268443 | - |
dc.description.abstract | BACKGROUNDS: It is unclear which patients benefit from resection in intermediate-stage-hepatocellular carcinoma (HCC). The authors aimed to identify high-risk patients for early recurrence among patients with resectable intermediate-stage HCC. METHODS: This multicenter retrospective study included patients who underwent resection or trans-arterial chemoembolization (TACE) for intermediate-stage HCC (2008-2019). Multivariable Cox proportional analysis was performed to identify high-risk patients when treated with resection. A prediction score for 2-year recurrence-free survival (RFS) was developed using the training cohort and validated. The 2-year RFS in each risk group was compared with that in TACE group, after propensity score matching (PSM). RESULTS: A total of 1686 patients were included (480 and 1206 patients in the resection and TACE groups). During a median follow-up of 31.4 months, the 2-year RFS was significantly higher in the resection (47.7%) than in the TACE group (19.8%) [adjusted hazard ratio (aHR)=1.471, 95% CI: 1.199-1.803, P <0.001). On multivariate analysis, alpha-fetoprotein ≥5.0 ng/ml (aHR=0.202), ALBI grade ≥2 (aHR=0.709), tumor number ≥3 (aHR=0.404), and maximal tumor size ≥5 cm (aHR=0.323) were significantly associated with the lower risk of 2-year RFS in the resection group. The newly developed Surgery Risk score in BCLC-B (SR-B score) with four significant risk factors showed an area under the curve of 0.801 for the 2-year RFS and was validated. Based on the SR-B score, low-risk patients had a significantly higher 2-year RFS (training: aHR=5.834; validation: aHR=5.675) than high-risk patients (all P <0.001) did. In a PSM cohort, a low-risk resection group had a significantly higher (aHR=3.891); a high-risk resection group had a comparable 2-year RFS to those treated with TACE (aHR=0.816). CONCLUSIONS: Resection may be beneficial for resectable intermediate-stage HCC based on the SR-B score. Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. | * |
dc.language | English | * |
dc.title | Identification of patients with favorable prognosis after resection in intermediate-stage-hepatocellular carcinoma | * |
dc.type | Article | * |
dc.relation.issue | 2 | * |
dc.relation.volume | 110 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 1008 | * |
dc.relation.lastpage | 1018 | * |
dc.relation.journaltitle | International journal of surgery (London, England) | * |
dc.identifier.doi | 10.1097/JS9.0000000000000941 | * |
dc.identifier.wosid | WOS:001164676800031 | * |
dc.identifier.scopusid | 2-s2.0-85185218546 | * |
dc.author.google | Lee | * |
dc.author.google | Han Ah | * |
dc.author.google | Minjong | * |
dc.author.google | Yoo | * |
dc.author.google | Jeong-Ju | * |
dc.author.google | Chun | * |
dc.author.google | Ho Soo | * |
dc.author.google | Park | * |
dc.author.google | Yewan | * |
dc.author.google | Kim | * |
dc.author.google | Hwi Young | * |
dc.author.google | Tae Hun | * |
dc.author.google | Seo | * |
dc.author.google | Yeon Seok | * |
dc.author.google | Sinn | * |
dc.author.google | Dong Hyun | * |
dc.contributor.scopusid | 김태헌(57125156300;57219781484) | * |
dc.contributor.scopusid | 김휘영(56493773500) | * |
dc.contributor.scopusid | 이민종(55917792000) | * |
dc.contributor.scopusid | 전호수(57215293394) | * |
dc.contributor.scopusid | 이한아(57190980926;5831162710) | * |
dc.date.modifydate | 20240601081000 | * |